Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL846613 | 0.95 | TRPV1 (0.62) | TRPV1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL846378 | 0.91 | TRPV1 (0.61) | TRPV1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL846038 | 0.85 | MEN1 (0.58) | TRPV1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL846178 | 0.85 | MEN1 (0.60) | TRPV1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL1577038 | 0.85 | TRPV1 (0.76) | TRPV1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL860203 | 0.84 | TRPV1 (0.71) | TRPV1RAB9A | |
| SCHEMBL846333 | 0.84 | TRPV1 (0.74) | TRPV1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL13991493 | 0.82 | HDAC1 (0.77) | TRPV1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL20509078 | 0.82 | HDAC1 (0.76) | TRPV1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL846266 | 0.82 | TRPV1 (0.50) | TRPV1HDAC1HDAC2HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | claimed |
| EP-1603883-B1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-28 | — | — | EP | claimed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | claimed |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-30 | — | — | US | claimed |
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| EP-1603883-B1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-28 | — | — | EP | disclosed |
| EP-2308848-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | Janssen Pharmaceutica NV (BE) | 2011-04-13 | — | — | EP | disclosed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | disclosed |
| EP-1603883-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-14 | — | — | EP | disclosed |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-30 | — | — | US | disclosed |
| WO-2004069792-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | TRPV1, OPRL1, TRPV2 | TRPV1 1/4885HDAC1 1481/4885HDAC2 1504/4885 |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | TRPV1, OPRL1, TRPV2 | TRPV1 1/4885HDAC1 1481/4885HDAC2 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.